GlassScriptPhysician profile
Sachin Wadhawan
NPI 1700023579
$4,372.96
in general payments reported to CMS, 2019-2025
26 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $87.97 · 2021: $140 · 2022: $720 · 2023: $945 · 2024: $1,137 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $766.39 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $454.88 | 2022-2025 | |
| Pfizer INC. | $439.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $362.79 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $285.96 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $266.43 | 2022-2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $258.19 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.61 | 2019-2025 | Jardiance |
| Cvrx, INC. | $179.34 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $172.12 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.56 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $127.22 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $95.75 | 2024-2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $73.06 | 2019 | |
| Scpharmaceuticals INC. | $70.59 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.52 | 2022-2025 | |
| Esperion Therapeutics, INC. | $54.97 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $53.07 | 2020-2021 | |
| Abbott Laboratories | $52.90 | 2024 | Jot Dx |
| Boston Scientific Corporation | $49.02 | 2023-2024 | Watchman Access System, Watchman Flx |
| Abiomed | $47.93 | 2024-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $38.15 | 2023-2024 | Inpefa |
| Heartflow, INC. | $33.31 | 2024 | |
| Amarin Pharma, INC. | $27.10 | 2019 | |
| Lantheus Medical Imaging, INC. | $14.16 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Wadhawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.